Skip to content

Study · Systematic review · 2024

4 results

Network meta-analysis of the risk of dyspepsia and anorexia in patients with type 2 diabetes mellitus induced by glucagon-like peptide 1 receptor agonist hypoglycemic drugs.

Jiao BL, Zhao J, Wang B, Liu BY, Wu T

European review for medical and pharmacological sciences1 Apr 2024Cited by 1 (Europe PMC)

PMID38708466 (opens in a new tab)DOI10.26355/eurrev_202404_36023 (opens in a new tab)PepBankPUB-38708466
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, liraglutide had the highest risk of dyspepsia among all interventions in the network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, liraglutide had the highest risk of indigestion among the drugs compared.

    Peptide
    Liraglutide
    Outcome
    IncreaseDyspepsia risk, rank among interventions
    Study

    n: not reported in source

    Comparator
    Other included interventions
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    liraglutide was the one with the highest risk of dyspepsia
    1 context sentence
    Summary · context
    Randomized Controlled Trials (RCTs) were collected in which the subjects were T2DM patients, the intervention was GLP-1RA compared with placebo or traditional hypoglycemic drugs, and the outcome indicators included dyspepsia and anorexia.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) carried 3.01 times the risk of dyspepsia versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group, liraglutide included, raised the risk of indigestion compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseDyspepsia risk, total GLP-1 RA
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Measurements

    Risk ratio for dyspepsia
    3.01 times placebo
    total GLP-1 RA

    Source sentences

    Summary
    The results of the traditional meta-analysis showed that the risk of dyspepsia and anorexia of total GLP-1 RA was 3.01 and 2.56 times that of placebo, respectively.
    1 context sentence
    Summary · context
    Randomized Controlled Trials (RCTs) were collected in which the subjects were T2DM patients, the intervention was GLP-1RA compared with placebo or traditional hypoglycemic drugs, and the outcome indicators included dyspepsia and anorexia.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) carried 2.56 times the risk of anorexia versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group, liraglutide included, raised the risk of loss of appetite compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseAnorexia risk, total GLP-1 RA
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Measurements

    Risk ratio for anorexia
    2.56 times placebo
    total GLP-1 RA

    Source sentences

    Summary
    The results of the traditional meta-analysis showed that the risk of dyspepsia and anorexia of total GLP-1 RA was 3.01 and 2.56 times that of placebo, respectively.
    1 context sentence
    Summary · context
    Randomized Controlled Trials (RCTs) were collected in which the subjects were T2DM patients, the intervention was GLP-1RA compared with placebo or traditional hypoglycemic drugs, and the outcome indicators included dyspepsia and anorexia.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with type 2 diabetes, all types of GLP-1RA (liraglutide among them) showed a trend towards increased digestive system adverse events versus placebo.

    In plain wordsIn adults with type 2 diabetes, all GLP-1 drug types, liraglutide included, tended to cause more digestive side effects than placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseDigestive system adverse events, all GLP-1RA types
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    All types of GLP-1RA were compared with placebo and the results also showed a trend towards increased risk of digestive system adverse events (DSAEs).
    1 context sentence
    Summary · context
    Randomized Controlled Trials (RCTs) were collected in which the subjects were T2DM patients, the intervention was GLP-1RA compared with placebo or traditional hypoglycemic drugs, and the outcome indicators included dyspepsia and anorexia.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.